Actively Enrolling Diabetic Retinopathy and DME Clinical Trials
Diabetic Retinopathy and Diabetic Macular Edema
Diabetic retinopathy (DR) stands as a significant cause of vision loss, particularly affecting the working-age population. In the United States alone, approximately eight million people are affected by this condition. DR arises as a complication of prolonged diabetes, resulting in damage to the delicate blood vessels and neural tissue of the retina.
Even in its early stages, DR impacts visual function, affecting contrast sensitivity, night vision, peripheral vision, and visual acuity. As the disease progresses, patients experience small hemorrhages throughout the retina, central retinal swelling, permanent loss of blood vessels, and the emergence of dangerous new blood vessels. These complications can lead to retinal detachment and severe glaucoma.
Thankfully, intervention can prevent or reverse these complications for the majority of patients. Treatment strategies often overlap with those used for wet macular degeneration. Ongoing research explores potential treatment options such as long-lasting molecules and cutting-edge gene therapy.
Below, we highlight some of the active studies at RCSD. Feel free to reach out to us to determine if any of these trials align with your needs.
ALTITUDE
Boehringer Ingelheim (Ingelheim am Rhein, Germany)
A phase II Trial in Patients With Geographic Atrophy: A Randomized, Double-masked, Placebo-controlled, Dose-finding Study to Evaluate the Efficacy and Safety of BI 1584862
PI: Nikolas JS London, MD FACS
Status: Active and enrolling
NIH registration: Clinicaltrials.gov
Sponsor website: Boehringer Ingelheim
Contact: [email protected]
THULITE
Boehringer Ingelheim (Ingelheim am Rhein, Germany)
This phase 2 study is open to adults 18 and older with diabetic macular edema. People are required to have a specific type of diabetic macular edema called centre-involved diabetic macular edema (CI-DME) to take part. The purpose of this study is to find out whether a medicine called BI 1815368 improves sight in people with CI-DME and to find the most suitable dose.
PI: Nikolas JS London, MD, FACS
Status: Active and enrolling
NIH registration: Clinicaltrials.gov
Sponsor website: Boehringer Ingelheim
Contact: [email protected]
Years in Practice in San Diego
We've been leading the way in retinal care and clinical research since 1979.